Dahlof C G, Rapoport A M, Sheftell F D, Lines C R
Gothenburg Migraine Clinic, Sweden.
Clin Ther. 1999 Nov;21(11):1823-36; discussion 1821. doi: 10.1016/S0149-2918(00)86731-4.
Rizatriptan is a selective 5-hydroxytriptamine1B/1D receptor agonist that was launched in 1998 for the acute treatment of migraine in adults. Based on data from 6 large clinical trials in patients > or =18 years of age in whom migraine was diagnosed according to International Headache Society criteria, the marketed 10-mg and 5-mg oral doses of rizatriptan are effective in relieving headache pain and associated migraine symptoms. The 10-mg dose is more effective than the 5-mg dose. At 2 hours after dosing, up to 77% of patients taking rizatriptan 10 mg had pain relief compared with 37% of those taking placebo, up to 44% were completely pain free compared with 7% of those taking placebo, and up to 77% were free of nausea compared with 58% of those taking placebo (P < 0.05 for all 3 comparisons). Both doses of rizatriptan are generally well tolerated. In placebo-controlled studies involving treatment of a single migraine attack, the most common side effects (incidence > or =2%) occurred in <10% of patients, typically were transitory (2 to 3 hours), and were mild or moderate. Rizatriptan is an effective and well-tolerated acute treatment for migraine.
利扎曲普坦是一种选择性5-羟色胺1B/1D受体激动剂，于1998年上市用于成人偏头痛的急性治疗。基于6项针对年龄≥18岁、根据国际头痛协会标准诊断为偏头痛的患者的大型临床试验数据，市售的10毫克和5毫克口服剂量的利扎曲普坦可有效缓解头痛疼痛及相关偏头痛症状。10毫克剂量比5毫克剂量更有效。给药后2小时，服用10毫克利扎曲普坦的患者中高达77%的人疼痛得到缓解，而服用安慰剂的患者中这一比例为37%；高达44%的人完全无痛，而服用安慰剂的患者中这一比例为7%；高达77%的人无恶心症状，而服用安慰剂的患者中这一比例为58%（所有3项比较的P均<0.05）。两种剂量的利扎曲普坦一般耐受性良好。在涉及单次偏头痛发作治疗的安慰剂对照研究中，最常见的副作用（发生率≥2%）发生在不到10%的患者中，通常是短暂的（2至3小时），且为轻度或中度。利扎曲普坦是一种有效且耐受性良好的偏头痛急性治疗药物。
